Abstract | BACKGROUND: STUDY DESIGN AND METHODS: RESULTS: Overall, 28 (85%) patients succeeded in collecting at least 2×10(6)/kg body weight (b.w.) CD34+ cells (median, 5.0×10(6)/kg b.w. CD34+ cells; range, 2.0×10(6)-29.5×10(6)/kg b.w. CD34+ cells), and five (15%) patients collected a median of 1.5×10(6)/kg b.w. CD34+ cells (range, 0.9×10(6)-1.8×10(6)/kg b.w. CD34+ cells). Nineteen patients proceeded to transplantation. The median dose of CD34+ cells infused was 3.3×10(6)/kg b.w. (range, 2.3×10(6)-6.7×10(6)/kg b.w. CD34+ cells). The median numbers of days to neutrophil and platelet engraftment were 11 (range, 9-12) and 15 (range, 10-25) days, respectively. CONCLUSION: These data emphasize the role of plerixafor in combination with G-CSF or chemotherapy and G-CSF as an effective mobilization regimen with the potential of successful stem cell collection. Accordingly, plerixafor seems to be safe and effective in patients with nonhematologic diseases. Larger prospective studies are warranted to further assess its use in these patients.
|
Authors | Nina Worel, Jane F Apperley, Grzegorz W Basak, Kenneth W Douglas, Ian H Gabriel, Catarina Geraldes, Kai Hübel, Ozren Jaksic, Zdenek Koristek, Francesco Lanza, Roberto Lemoli, Gabor Mikala, Dominik Selleslag, Rafael F Duarte, Mohamad Mohty |
Journal | Transfusion
(Transfusion)
Vol. 52
Issue 11
Pg. 2395-400
(Nov 2012)
ISSN: 1537-2995 [Electronic] United States |
PMID | 22414093
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | © 2012 American Association of Blood Banks. |
Chemical References |
- Anti-HIV Agents
- Antineoplastic Agents
- Benzylamines
- Cyclams
- Heterocyclic Compounds
- Granulocyte Colony-Stimulating Factor
- plerixafor
|
Topics |
- Adolescent
- Adult
- Aged
- Anti-HIV Agents
(therapeutic use)
- Antineoplastic Agents
(therapeutic use)
- Benzylamines
- Blood Component Removal
(methods)
- Bone Neoplasms
(drug therapy)
- Child
- Child, Preschool
- Combined Modality Therapy
- Cyclams
- Europe
- Female
- Granulocyte Colony-Stimulating Factor
(therapeutic use)
- Hematopoietic Stem Cell Mobilization
(methods)
- Heterocyclic Compounds
(therapeutic use)
- Humans
- Male
- Middle Aged
- Neoplasms
(drug therapy)
- Neoplasms, Germ Cell and Embryonal
(drug therapy)
- Neuroblastoma
(drug therapy)
- Sarcoma, Ewing
(drug therapy)
- Stem Cell Transplantation
(methods)
- Wiskott-Aldrich Syndrome
(drug therapy)
- Young Adult
|